General
Preferred name
VADADUSTAT
Synonyms
AKB-6548 ()
PG-1016548 ()
AKB-6548, B-506, PG-1016548 ()
PG1016548 ()
B506 ()
B-506 ()
P&D ID
PD058840
CAS
1000025-07-9
Tags
available
drug
Approved by
PMDA
EMA
First approval
2020
Drug Status
investigational
approved
Drug indication
Anaemia
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Vadadustat is an orally bioavailable HIF prolyl-hydroxylase inhibitor. It targets the enzymes PHD1, PHD2 and PHD3 to mediate an increase in endogenous erythropoietin production which delivers anti-anemia action. See also . (GtoPdb)
Compound Sets
15
Axon Medchem Screening Library
3288
Cayman Chemical Bioactives
15295
ChEMBL Drugs
CHEMBL3646221
Drug Repurposing Hub
DrugBank
DB12255
DrugBank Approved Drugs
DB12255
DrugCentral
5420
DrugCentral Approved Drugs
5420
DrugMAP
DM2EJM3
EU-OPENSCREEN Bioactive Compound Library
EOS100141
Guide to Pharmacology
11831
MedChem Express Bioactive Compound Library
HY-101277
ReFrame library
Selleckchem Bioactive Compound Library
vadadustat
TargetMol Bioactive Compound Library
T4651
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
306.04
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
1.92
TPSA
99.52
Fraction CSP3
0.07
Chiral centers
0.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Angiogenesis
Chromatin/Epigenetic
Metabolic Enzyme/Protease
Target
HIF-PH
HIF-PH inhibitor
HIF/HIF Prolyl-Hydroxylase
MOA
HIF
HIF Prolyl-Hydroxylase
hypoxia inducible factor prolyl hydroxylase inhibitor
Source data